Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0017638 (glioma)
 30,880 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Sixty-three patients with malignant glioma undergoing chemotherapy and radiotherapy were evaluated with electroencephalography, 99mTc-DTPA imaging, and computed tomography (CT). Tumor size, central lucency, contrast enhancement, surrounding edema, and ventricular size were assessed. CT findings were found to be reliable and often predicted the clinical course. Tumor size, central lucency, and contrast enhancement increased in patients with clinical deterioration and decreased in those with improvement. The CT scan also provided additional information of value in adjunctive therapy, such as the presence of cysts or ventricular obstruction. In general, CT gave a more complete profile of tumor characteristics than other diagnostic modalities.
 ...
PMID:Computed tomography in the evaluation of malignant glioma before and after therapy. 108 56

Sequential MR imaging with gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA) and sequential measurements of plasma Gd-DTPA concentration by inductively coupled plasma atomic emission spectroscopy (ICP-AES) were used to estimate the blood-to-tissue transport coefficient (Ki) in the 36B-10 rat glioma model. For these measurements, tissue Gd-DTPA concentration was estimated from tumor enhancement by correlation with calibration measurements obtained by ICP-AES analysis of tumor tissue. The 14 animals for which Ki was calculated can be grouped into those imaged at 11 days following tumor implantation, at 13-18 days, and at 20 days. The mean (+SEM) Ki values for these groups were 1.1 + 0.24, 9.2 + 0.8, and 13.4 + 1.7 ml/kg-min, respectively. These results correspond well with published data obtained by quantitative autoradiography. It is concluded that frequent sequential imaging and a graphical approach to Ki calculation are promising methods for determining the blood-to-tissue transport coefficient noninvasively by contrast-enhanced MRI.
 ...
PMID:Measurement of blood-brain barrier permeability in a tumor model using magnetic resonance imaging with gadolinium-DTPA. 143 11

The MR examinations in 25 patients with intramedullary tumors were analyzed. Seven patients were diagnosed with astrocytoma, 6 ependymoma, 2 unspecified glioma, 3 medulloblastoma, 2 metastasis, one neurinoma, and one teratoma. In 3 patients the diagnosis was uncertain. The tumors frequently involved a large portion of the cord and were often accompanied by intratumor necrosis, cystic degeneration, and edema, which was well demonstrated on MR. Gd-DTPA was used in 6 patients and was helpful in separating solid tumor components from cysts and edema. It was difficult to separate different kind of tumors based on morphologic and signal characteristics on MR. Some prominent features could, however, be distinguished. Complete cystic degeneration was more common in astrocytomas than in other tumors, and ependymomas frequently had a heterogeneous signal pattern on both T1- and T2-weighted sequences. The single teratoma had a characteristic content of fat and calcification, and the melanoma had a signal pattern consistent with blood. CSF pathway spread in cases of medulloblastoma was demonstrated by ill-defined contour of the cord and CSF or tumor nodules on the surface of cord and nerve roots.
 ...
PMID:MR imaging of spinal intramedullary tumors. 166 Feb 97

CT and MRI were used in a prospective study of the central nervous system (CNS) manifestations in 41 consecutive children with neurofibromatosis type 1 (NF-1). Gadolinium-DTPA was used in 15 patients. MRI was more effective than CT in delimiting the extension of the optic pathway glioma and in evaluating associated cerebral malformations. MRI visualized lesions generally undetected by CT, in the form of iso- or hyperintense foci with respect to the cerebral cortex in T2-weighted sequences. Well-delimited lesions of high signal intensity were observed in the globus pallidus (22 cases), the internal capsule (6 cases), corpus callosum (2 cases), anterior commissure (1 case) and semioval center (2 cases). Poorly defined hyper- or isointense areas were also observed affecting the cerebellar white matter (21 cases) and brain stem (17 cases). None of these lesions showed Gadolinium-DTPA enhancement, and were of no clinical significance. MRI has displaced CT in the initial diagnosis of patients with NF-1. Periodic annual MRI controls are only justified in patients with MRI changes to evaluate the progression or stabilization of the lesions.
 ...
PMID:Imaging considerations of central nervous system manifestations in pediatric patients with neurofibromatosis type 1. 174 66

Intravenous administration of hyperosmotic mannitol into rats produced a disruption of the blood-brain barrier (BBB). This was visualized by T1 weighted magnetic resonance (MR) imaging following intravenous administration of the MR contrast agent gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA). Following administration of the Gd-DTPA there was an increase in signal intensity corresponding to the cerebral cortex. There was also an increase in signal intensity in features corresponding to the lateral ventricles. However, there was no increase in signal intensity within the striatum indicating that the vasculature within the striatum was resistant to disruption by the hyperosmotic mannitol. The tumors formed by C-6 glioma cells were isointense with rat brain on precontrast MR images. Following intravenous administration of Gd-DTPA, in a representative rat, the tumor was visualized as areas of high signal intensity. There was no enhancement of normal brain by Gd-DTPA. Thus, the tumor had different vascular properties than the host brain with respect to permeability of the contrast agent. Furthermore, Gd-DTPA did not enter the normal brain via the tumor. Thirty days following unilateral injection of kainic acid (KA: 5 nmol) into rat striatum, the shrinkage of the lesioned striatum and the concomitant enlargement of the lateral ventricles was visible on the precontrast MR images. Following administration of Gd-DTPA, there was no enhancement of any regions of the brain. Therefore, the structural perturbations of the striatum produced by KA lesions were not accompanied by disruption of the BBB. These studies demonstrate that MR imaging represents a useful technique for investigating in vivo the perturbation of the cerebral vasculature in rat models of neuropathologies.
 ...
PMID:Magnetic resonance imaging of rat brain following in vivo disruption of the cerebral vasculature. 190 78

Using RG-C6 glioma-transplanted rats, we studied precontrast and postcontrast magnetic resonance imaging, extravasation of Evans blue, and histology. In all rats, tumor was enhanced with gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA). The necrotic portion in the tumor, however, was not enhanced. Hemorrhage and hydrocephalus were clearly visualized on both the precontrast and postcontrast images. Blood-brain barrier-disrupted areas stained with Evans blue and areas enhanced with Gd-DTPA on magnetic resonance imaging were nearly consistent. It is suggested that the mechanism of brain tumor enhancement with Gd-DTPA on magnetic resonance imaging is simply related to the degree of alteration of the blood-brain barrier. The Gd-DTPA-enhanced magnetic resonance imaging, even with low magnetic field, is useful for the evaluation of size, shape, and location of experimental rat brain tumors.
 ...
PMID:Magnetic resonance imaging of experimental rat brain tumors: histopathological evaluation. 224 1

A monoclonal antibody (MUC 2-63) was raised against a neuroectodermal antigen expressed on human malignant gliomas, neuroblastomas and melanomas. The mouse monoclonal antibody MUC 2-63 was of IgG1 isotype, it binds the antigenic determinants with the molecular weight of 32,000 Dalton present on the cell surface of native glioma cells. Seven patients with brain tumours, five with biopsy proven malignant gliomas, received an intravenous injection of the 111In-DTPA coupled monoclonal antibody MUC 2-63. Six patients had an uptake of 0.01-0.04% of the injected dose at the site of the tumour, which correlated to the computerized tomography (CT) images. The half-lives in the tumours of 111In were 38-259 h. The maximal uptake in the tumours were noticed between 40 and 67 h. One patient failed to demonstrate any intracranial uptake of the radioactivity. This patient had been treated with surgery and radiotherapy for a stage 2 testicular seminoma four years ago. He recently developed clinical signs of a primary brain tumour and the CT diagnosis was malignant glioma. All patients had nonspecific uptake in the liver, half-lives were between 60 and 84 h, the corresponding maximal uptake was detected between 22 and 45 h. No side effects were observed by administration of the mouse monoclonal antibody MUC 2-63.
 ...
PMID:Radioimaging of human malignant gliomas using indium-labelled monoclonal antibodies. 238 29

MR images of 55 gliomas (23 malignant gliomas, 16 Grade I-II astrocytomas, 7 oligodendrogliomas, 5 pontine gliomas, 2 central neurocytomas and 2 ependymomas) were reviewed. Histological diagnosis was obtained in all of these gliomas. Morphologic appearance and signal intensities of each glioma were evaluated on T1 and T2 weighted images. Nearly isointensity areas which correspond to enhanced areas on CT scans were observed in all malignant gliomas, and 19 of 23 malignant gliomas (83%) showed heterogeneous intensities on MR images. On the other hand, 12 of 16 benign astrocytomas (75%), 5 of 7 oligodendrogliomas (71%) and all of 5 pontine gliomas showed homogeneous intensities. All of central neurocytomas and ependymomas were shown as a solid tumor with cysts and heterogeneous intensities. In conclusion, although MR images without Gd-DTPA seemed not to be superior to contrast CT in differentiating malignant gliomas from benign one, it appears significant to know some tissue characteristics on MR images of gliomas in differentiating from the other brain tumors.
 ...
PMID:[MR images of gliomas]. 238 1

Gd(DO3A), a member of a new family of nonionic MRI contrast agents, was evaluated in vivo in a rat model. In 10 animals, enhancement of an intracerebral glioma was studied following Gd(DO3A) injection. Correlation with tissue pathology was obtained in all cases. Comparative studies of renal enhancement were performed in 15 animals, utilizing disodium Gd(DTPA)2-, sodium-Gd(DOTA)-, and Gd(DO3A). With the glioma model, Gd(DO3A) administration provided enhancement of tissue with an altered blood brain barrier, thus permitting identification of the bulk of the neoplastic lesion. Comparative studies revealed that enhancement of normal renal medulla was equal or superior with Gd(DO3A).
 ...
PMID:Experimental trials with Gd(DO3A)--a nonionic magnetic resonance contrast agent. 260 11

The tumors formed by rat C-6 glioma cells were isointense with the normal rat brain on precontrast T1 weighted magnetic resonance (MR) images. Following i.v. peripheral administration of the MR imaging contrast agent gadolinium (Gd)-DTPA, there was no significant change in the signal intensity from normal brain tissue. However, the tumor appeared as areas of high signal intensity demonstrating the abnormal vascular properties of the tumor. Fetal rat striatal tissue transplanted into unlesioned adult rat striatum appeared isointense with the host brain on precontrast T1 weighted images and there was no evidence for enhancement of the transplanted tissue relative to host brain following i.v. administration of Gd-DTPA. Using this technique we found no evidence with respect to permeability of the contrast agent of an abnormal blood-brain barrier within the striatal transplant in vivo.
 ...
PMID:A magnetic resonance imaging contrast agent differentiates between the vascular properties of fetal striatal tissue transplants and gliomas in rat brain in vivo. 261 48


1 2 3 4 5 6 7 8 9 Next >>